Rigel Pharma Moves Forward With Midstage COVID-19 Study

Health and Healthcare

Published: September 17, 2020 12:37 pm

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19. With the ongoing pandemic resulting in thousands of new cases every day, this trial offers another option in the treatment against this disease.

In terms of the specifics, the firm is initializing its Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients.

The study is sponsored by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, in collaboration with Inova Health System. Fostamatinib, which marketed in the United States as Tavalisse tablets, is approved in the United States and Europe as a treatment for adult chronic immune thrombocytopenia.

As for the structure of the trial, it is a randomized, double-blind, placebo-controlled trial to evaluate the safety of fostamatinib for the treatment of hospitalized COVID-19 patients. The study will randomly assign fostamatinib or a placebo to roughly 60 evaluable patients.

The treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60. The primary objective of this study is to evaluate the safety of fostamatinib compared to placebo for the treatment of hospitalized COVID-19 patients. The secondary objective will be to assess the early efficacy and clinically relevant measures of disease progression.

Excluding Thursday’s move, Rigel Pharmaceuticals stock had outperformed the broad markets with a gain of about 17% year to date. In the past 52 weeks, the stock was up closer to 51%.

Rigel Pharmaceuticals stock traded about 5% on Thursday to $2.64, in a 52-week range of $1.23 to $5.24. The consensus price target is $7.33.

24/7 Wall St.
5 Turnaround Stocks Getting Some Traction on Wall Street

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!